2022年2月8日 · Although serum KL-6 is a stable biomarker that is not affected by lung infection and smoking status, those in the IPF arm with antinuclear antibodies demonstrated higher KL-6 levels. KL-6 levels, along with poor pulmonary function and high radiologic fibrosis scores, are indicative of the severity of an individual’s IPF, but not of poor survival.

2019年1月30日 · Other predictive markers include chemokine (C-C motif) ligand 18 (CCL18) for progression of ILD and Krebs von den Lungen-6 (KL-6) for acuteness of lung fibrosis. The 2 study cohorts included a total of 427 individuals with SSc. Pulmonary function tests and high-resolution computed tomography (HRCT) were used to examine lung fibrosis ...

2022年12月7日 · Potential soluble biomarkers in peripheral blood/bronchoalveolar lavage fluid (BALF) for the diagnosis of systemic sclerosis interstitial lung disease (SSc-ILD) include Krebs von den Lungen-6 (KL-6), surfactant protein-D (SP-D), and interleukin-8 (IL-8), according to a systematic review and meta-analysis published in Thorax.

2023年4月13日 · “Ca15-3 may be a lower-cost, more accessible surrogate for KL-6 in future biomarker assessment.” Disclosure: Research grants for this study were received from Arthritis Australia and Roche Pharmaceuticals. Some of the study authors declared affiliations with biotech, pharmaceutical, and/or device companies.

2020年4月16日 · With a median follow-up of 31 months, adverse events were reported in 37.6% of the participants. Considering the study population as a whole, treatment outcomes included an unsuccessful outcome in 35.3% of the participants. Treatment was discontinued in 13.5%of patients and treatment failure occurred in 4.1% of patients.

2022年9月20日 · Veterans reporting blast exposure were more likely to experience respiratory symptoms, including cough, dyspnea, and wheezing, as well as an aggregate assessment of reporting any severe respiratory symptoms (odds ratio [OR], 2.2; 95% CI, 1.6-3.0), compared with those not exposed to blasts.

2018年1月29日 · The incidence ratio was 6.05 for admission for acute MI during the risk interval vs the control interval. After day 7 there was no increased incidence. The incidence ratios were 10.11, 5.17, 3.51, and 2.77 for acute MI within 7 days of detection of influenza B, influenza A, respiratory syncytial virus, and other viruses, respectively.

5 天之前 · The typical period for review is 10 months after the drug application has been accepted by the Agency. For drugs that have Priority Review, the review period is reduced to 6 months from the time of application acceptance. Reproxalap for Dry Eye Disease. PDUFA date: April 2, 2025

2023年5月22日 · A sensitivity analysis of 2845 patients using full optimal matching showed no significant between-group differences in the occurrence of in-hospital death or discharge to hospice care (aRD, -0.6%; 95% CI, -3.7% to 2.4%; P =.68)

2019年7月30日 · 5. Aaron SD, Vandemheen KL, Ferris W, et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet. 2005;366(9484):463-471. 6.